Depression is the leading cause of disability in developed countries, and it is a source of some amazement that in 2016 so little progress had been made in developing new therapeutic agents for this, and other psychiatric diseases. There had been a clear path forward for almost 10 years, charted by the successes with other complex conditions such as heart disease and diabetes: collection of well-powered samples for genetic analysis, the identification of genes unambiguously involved in the phenotype, and the development of drugs based on understanding what those genes do. Indeed, it is known that the chances of a drug's success are about 4-fold higher when it has support from genetic evidence. When focused research efforts into the genetics of mental disease have taken place, great progress in the identification of associated genes has been made-as success with autism and schizophrenia demonstrates. So I'd argue that current failure to develop effective therapies based on such knowledge is more a sociological than a scientific challenge. What will it take to convince funding agencies to invest in this area? Depression is costing the economies of developed countries more than diabetes and cancer, but while many states have National Institutes of Cancer and Diabetes, none have a National Institute of Depression. I can think of many reasons why this is so, but I can't think of any good excuses.
Medicines Rooted in Mechanism
Michael D. Ehlers
Biogen
Just as the revolution in molecular biology and immunology helped usher in the modern era of cancer therapeutics, we are witnessing an explosion of knowledge and technology that is unraveling the inner workings of the brain. The complex genetic underpinnings of neuropsychiatric disease are emerging, but converting multigenic risk into tractable mechanisms, targets, and pathways remains nascent. Even as genetics defines molecular targets at the causal core of disease, we need better means to assess relevant brain circuits and functional domains such as cognition, motivation, and emotional valence in patients. Optogenetics, imaging, and electrophysiological approaches are transforming our ability to monitor and manipulate neural circuits in mice and monkeys. Now, the challenge will be linking these approaches to non-invasive circuit biomarkers and neuropsychological domain assessments in the clinic. For most neuropsychiatric diseases, we need much more natural history data to define biomarkers predictive of disease course, severity, and treatment response. Such longitudinal studies are critical to define the roadmap for reverse engineering mental illness. Ultimately for a new drug to reach patients, safety and efficacy must be demonstrated in a defined patient population. To fully realize the new neurobiology of mental illness, current categorization of disease states by symptom cluster must be replaced or augmented by definitions that reflect their biological basis. Advances in human genetics are reshaping the way we understand many mental illnesses including schizophrenia. We know infinitely more about the DNA changes that are part of the risk of becoming ill, with a key finding being their overall number and variety. The critical next step is to learn how they produce disease. Currently, biological investigation of genetic risks proceeds in a gene-by-gene fashion, which is slow and expensive. There has also been a focus on identifying variants that confer strong risk for disease, and in my view, when looking at the genetic factors conferring susceptibility to schizophrenia, more attention needs to be provided to studies of the plethora of variants that cause small to moderate risk. Thus we will need to adapt methods that allow multiple genes and variants to be studied simultaneously in a more global, unbiased manner. Genetic results suggest that in addition to coding variant risk, a substantial role for regulatory variation exists. Gaining insight into how these regulatory variants influence risk will require production of comprehensive maps of genomic gene expression and regulatory regions, such as enhancers and promoters in human brain tissue as well as in individual human neuronal subtypes. These efforts are gaining traction in several consortium projects such as the CommonMind Consortium, the Lieber Institute for Brain Development, and the PsychENCODE project. Given the limited availability of brain tissue, iPS-derived neuronal cell lines will provide another important resource for characterizing risk genes, particularly as large libraries of engineered cell lines are created on isogenic backgrounds. Pushing hard on iPS technologies is a must since they would naturally be a convenient platform for small molecule screens to aid in the development of novel therapeutics.
Fund Innovative Research
Jeffrey Borenstein Brain & Behavior Research Foundation Since the war on cancer was declared almost 50 years ago, billions of dollars have poured into cancer research. Only a fraction of those dollars are spent on mental health research, though it is impossible to overstate its economic, social and personal toll on society.
We need to declare war on mental illness, which affects the lives of one in four people, and place a priority on funding innovative neurobiological research for better prevention, diagnosis, early intervention, and treatment.
The field has seen tremendous scientific advances, but we need to expand basic, translational and clinical research to better understand the workings of the brain and why things go wrong, and test new medical and psycho-social approaches. We also need to raise awareness, eliminate stigma, and remove barriers to treatment.
At the same time, we are at risk of losing an entire generation of young scientists. Scarce resources mean more competition for federal grants, lab closures, and fewer incentives to pursue scientific careers. The Brain & Behavior Research Foundation is combating brain drain through a funding model that supports scientists at every stage of their careers, and gives young investigators a leg up.
We believe a combination of public and private funding for high-risk, high reward research will generate significant scientific discoveries that will change lives and end the suffering that psychiatric illness brings so many.
Harness New Technologies

Steven E Hyman
Broad Institute of MIT and Harvard We must take on the difficulties that have impeded progress for the last 50 years: the lack of molecular mechanisms, the inaccessibility of living human brain tissue, the limitations of what can be modeled in animals, and the lack of objective diagnoses and biomarkers. Fortunately, new technologies, beginning with large-scale unbiased genetics, are illuminating a path. How can we transform gene lists into useful biology? We can employ human cells reprogrammed into specific neural types. We must, however, use isogenic lines and patient-derived lines wisely with great respect for their intrinsic variability. We can use single-cell methods to track down expression of risk alleles or introduce (or correct) them using new genome-engineering technologies. We can make biochemical quantities of cells in vitro or generate organoids to study development. But we must also check our answers where possible against postmortem human tissue and where appropriate against animal brains. We must use animal models to study basic mechanisms but should not delude ourselves into thinking that we can produce disease models. Where we require a model for a human neocortex, we should turn, where possible, to primates. We must use genetics in the clinic as well, to generate new ideas for biomarkers and to stratify both epidemiological and clinical trials populations. Nothing will be easy, but success seems possible.
